The Shanghai Institute of Materia Medica of the Chinese Academy of Sciences has synthesized new polycyclic heteroaryl compound acting as glucagon-like peptide 1 receptor (GLP-1R) agonists potentially useful for the treatment of diabetes and obesity, among others.